Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Crispr Therapeutics AG (CRSP – Research Report).
Globus Medical (GMED)
In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Globus Medical. The company’s shares closed last Wednesday at $54.24.
According to TipRanks.com, Turkaly is a 1-star analyst with an average return of
Globus Medical has an analyst consensus of Moderate Buy, with a price target consensus of $66.56, which is a 24.3% upside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
Crispr Therapeutics AG (CRSP)
In a report released today, Tyler Van Buren from TD Cowen maintained a Sell rating on Crispr Therapeutics AG, with a price target of $30.00. The company’s shares closed last Wednesday at $81.07.
According to TipRanks.com, Buren is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $84.10 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMED:
- Globus Medical Reports Fourth Quarter and Full Year 2023 Results
- Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call
- Globus Medical Promotes Keith Pfeil to COO and CFO
- Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer
- Globus Medical promotes Keith Pfeil as COO and Chief Financial Officer
